GT200200184A - Formulaciones farmaceuticas - Google Patents

Formulaciones farmaceuticas

Info

Publication number
GT200200184A
GT200200184A GT200200184A GT200200184A GT200200184A GT 200200184 A GT200200184 A GT 200200184A GT 200200184 A GT200200184 A GT 200200184A GT 200200184 A GT200200184 A GT 200200184A GT 200200184 A GT200200184 A GT 200200184A
Authority
GT
Guatemala
Prior art keywords
prospected
release
pharmaceutical formulations
synthrics
hypropressive
Prior art date
Application number
GT200200184A
Other languages
English (en)
Inventor
John Douglas Davis
Michael John Humphrey
Ross James Macrae
Janet Sarah Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200200184A publication Critical patent/GT200200184A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A FORMULACIONES FARMACEUTICAS ORALES DE LIBERACION CONTROLADA DE COMPUESTOS ANTAGONISTAS DE RECEPTORES ALFAADRENERGICOS QUE INCLUYEN A LA 4AMINO6,7DIMETOXI2(5METANOSULFONAMIDO1,2,3,4TETRAHIDROISOQUINOL2IL)5(2PIRIDIL) QUINAZOLINA Y SUS SALES FARMACEUTICAMENTE ACEPTABLES. EL OBJETO DE LA SOLICITUD ES EL DE MODIFICAR LA VELOCIDAD DE LIBERACION DEL FARMACO PARA PRODUCIR UNA LIBERACION CONSTANTE EN EL TRACTO GASTROINTESTINAL EN EL QUE EL PRINCIPIO ACTIVO ES DE UTILIDAD EN CASOS DE HIPERTENSION, INSUFICIENCIA CARDIACA CONGESTIVA, HIPERPLASIA PROSTATICA BENIGNA, ENTRE OTROS DESCRITOS EN EL EXPEDIENTE.
GT200200184A 2001-10-11 2002-09-17 Formulaciones farmaceuticas GT200200184A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0124455.7A GB0124455D0 (en) 2001-10-11 2001-10-11 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
GT200200184A true GT200200184A (es) 2003-05-23

Family

ID=9923660

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200200184A GT200200184A (es) 2001-10-11 2002-09-17 Formulaciones farmaceuticas

Country Status (32)

Country Link
EP (1) EP1434570B8 (es)
JP (1) JP4131471B2 (es)
KR (1) KR20050032510A (es)
CN (1) CN1568180A (es)
AP (1) AP2004003001A0 (es)
AR (1) AR036782A1 (es)
AT (1) ATE303135T1 (es)
BR (1) BR0213196A (es)
CA (1) CA2461168A1 (es)
CO (1) CO5560534A2 (es)
DE (1) DE60205925T2 (es)
DK (1) DK1434570T3 (es)
DO (1) DOP2002000464A (es)
EA (1) EA006168B1 (es)
ES (1) ES2246017T3 (es)
GB (1) GB0124455D0 (es)
GT (1) GT200200184A (es)
HR (1) HRP20040261A2 (es)
HU (1) HUP0600064A3 (es)
IL (1) IL160969A0 (es)
IS (1) IS7179A (es)
MA (1) MA27075A1 (es)
MX (1) MXPA04003293A (es)
NO (1) NO20041520L (es)
OA (1) OA12709A (es)
PA (1) PA8556001A1 (es)
PE (1) PE20030551A1 (es)
PL (1) PL369666A1 (es)
SV (1) SV2004001279A (es)
UY (1) UY27477A1 (es)
WO (1) WO2003032956A1 (es)
ZA (1) ZA200401976B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
HUE046285T2 (hu) 2013-03-14 2020-02-28 Amgen Inc Omecamtiv mecarbil sói és eljárás a só elõállítására
KR101943592B1 (ko) 2017-08-31 2019-01-30 조현우 데이터 마이닝 기법을 이용한 전자가계부 시스템

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69008526T2 (de) * 1990-07-02 1994-08-18 Bend Res Inc Asymmetrische mikroporöse Kügelchen für regulierbare Freigabe.
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
UA72311C2 (uk) * 2000-03-03 2005-02-15 Пфайзер Інк. Мезилат 4-аміно-6,7-диметокси-2-(5-метансульфонамідо-1,2,3,4-тетрагідроізохінол-2-іл)-5-(2-піридил)хіназоліну та поліморфні форми

Also Published As

Publication number Publication date
PE20030551A1 (es) 2003-06-26
DE60205925D1 (de) 2005-10-06
EP1434570A1 (en) 2004-07-07
HUP0600064A2 (en) 2006-06-28
HRP20040261A2 (en) 2004-08-31
KR20050032510A (ko) 2005-04-07
SV2004001279A (es) 2004-02-19
OA12709A (en) 2006-06-26
CA2461168A1 (en) 2003-04-24
EP1434570B8 (en) 2005-10-26
MA27075A1 (fr) 2004-12-20
NO20041520L (no) 2004-04-05
EA200400431A1 (ru) 2004-08-26
EP1434570B1 (en) 2005-08-31
DE60205925T2 (de) 2006-06-08
AR036782A1 (es) 2004-10-06
BR0213196A (pt) 2004-08-31
CO5560534A2 (es) 2005-09-30
DK1434570T3 (da) 2005-11-07
WO2003032956A1 (en) 2003-04-24
GB0124455D0 (en) 2001-12-05
JP2005507909A (ja) 2005-03-24
ATE303135T1 (de) 2005-09-15
IL160969A0 (en) 2004-08-31
CN1568180A (zh) 2005-01-19
HUP0600064A3 (en) 2007-02-28
UY27477A1 (es) 2003-05-30
IS7179A (is) 2004-03-11
DOP2002000464A (es) 2003-04-15
PL369666A1 (en) 2005-05-02
AP2004003001A0 (en) 2004-03-31
JP4131471B2 (ja) 2008-08-13
PA8556001A1 (es) 2003-07-28
ES2246017T3 (es) 2006-02-01
EA006168B1 (ru) 2005-10-27
ZA200401976B (en) 2004-07-12
MXPA04003293A (es) 2004-07-23

Similar Documents

Publication Publication Date Title
JP2005531516A5 (es)
NO2019005I1 (no) N-[2-(dietylamino)etyl]-5-[(Z)-(5-fluoro-2-okso-1,2-dihydro-3H-indol-3-yliden)metyl]-2,4-dimetyl-1H-pyrrol-3-karboksamid (sunitinib), samt farmasøytisk akseptable salter
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
JP2004501930A5 (es)
NO20082988L (no) Vedvarende frigivningsformulering innbefattende oktreotid og to eller flere polylaktid-ko-glykolidpolymerer
DE60232496D1 (de) Tabletten, die in der mundhöhle schnell zerfallen
GT199900184A (es) Formulaciones farmaceuticas de liberacion controlada.
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
PE20090705A1 (es) Derivados de uracilo en el tratamiento de hepatitis c
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
ECSP055568A (es) Composición de comprimido de liberación sostenida de pramipexol
ATE468332T1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin- - yi)aminderivate
DK1723144T3 (da) Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
LU91867I2 (fr) Fingolimod et ses dérivés pharmaceutiquement acceptables (GILENYA®)
GEP20053675B (en) Pyridazinone Aldose Reductase Inhibitors
CY1106606T1 (el) Διϋδροξυπυριμιδινο καρβοξαμιδια αναστολεις της ιντεγκρασης του hiv
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
PE20061373A1 (es) Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
PE20061394A1 (es) Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
CY1105479T1 (el) Παραγωγα τετραζολιου και μεθοδοι αντιμετωπισης σχετιζομενων με τον μεταβολισμο διαταραχων με αυτα
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
ATE516016T1 (de) Selbstemulgierende formulierungen von cetp- hemmern
ATE384058T1 (de) Thiazolderivate
ATE424821T1 (de) Pyrrolopyridin-2-karbonsäureamide